fosaprepitant

Known as: Fosaprepitantum 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
051020072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND Concurrent chemotherapy radiation therapy may result in significant nausea and vomiting. There have been few studies… (More)
Is this relevant?
2014
2014
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is one of… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
The incidence of postoperative nausea and vomiting (PONV) is 30-50% after surgery. PONV occurs frequently, especially after… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2013
2013
BACKGROUND We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2013
2013
Fosaprepitant dimeglumine for injection is the water-soluble phosphorylated prodrug of the neurokinin-1 receptor antagonist… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
The type 1 neurokinin receptor (NK1R) antagonist aprepitant and its i.v. prodrug fosaprepitant have been approved for prevention… (More)
Is this relevant?
2011
2011
PURPOSE Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves… (More)
Is this relevant?
2011
2011
Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5-HT(3) receptor antagonist, are used to… (More)
Is this relevant?
2009
2009
BACKGROUND A single 115-mg dose of fosaprepitant, the IV prodrug of the NK(1) receptor antagonist aprepitant, is bioequivalent to… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and… (More)
  • table I
  • table II
  • table III
  • table IV
  • table V
Is this relevant?